PSM retrospective 2,785 hospitalized patients in the USA, showing lower mortality and higher ventilation and ICU admission with aspirin treatment.
|
risk of death, 35.0% lower, OR 0.65, p = 0.04, treatment 319, control 319, propensity score matching, RR approximated with OR.
|
|
risk of mechanical ventilation, 49.0% higher, OR 1.49, p = 0.04, treatment 319, control 319, propensity score matching, RR approximated with OR.
|
|
risk of ICU admission, 45.0% higher, OR 1.45, p = 0.02, treatment 319, control 319, propensity score matching, RR approximated with OR.
|
|
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
|
Goshua et al., 5 Nov 2020, retrospective, USA, peer-reviewed, 15 authors.
Admission Rothman Index, Aspirin, and Intermediate Dose Anticoagulation Effects on Outcomes in COVID-19: A Multi-Site Propensity Matched Analysis
MD George Goshua, Yiwen Liu, MSc Matthew L Meizlish, MD Rebecca Fine, PharmD Kejal Amin, MD Eric Chang, MD Yuxin Liu, PharmD Dayna Mcmanus, PharmD Adina Petrosan, Cassius Ilya Ochoa Chaar, MD Hyung J Chun, PharmD Nicholas A Defilippo, ScD Donna S Neuberg, PharmD Kent A Owusu, MD PhD Alfred Ian Lee
Blood, doi:10.1182/blood-2020-143349
Introduction: Venous thromboembolism and in-situ small vessel thrombosis are increased in hospitalized patients with COVID-19 in several patient cohorts. Endotheliopathy and activation of both platelets and coagulation predict critical illness and death. For these reasons the use of anti-platelet agents and increased-intensity anticoagulation in the care of hospitalized patients with COVID-19 is under
Disclosures Neuberg: Pharmacyclics: Research Funding; Madrigak Pharmaceuticals: Current equity holder in publicly-traded company; Celgene: Research Funding.
Author notes * Asterisk with author names denotes non-ASH members.
© 2020 by the American Society of Hematology
